STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites revised (93)v28
  2. Study sites: 94 to 93v27
  3. Study sites: 79 to 94v26
  4. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 102 to 79
    v25
  5. Study sites revised (102)v24
Show 22 earlier versionsHide 22 earlier versions
  1. Site details revised at 7 of 102 sitesv23
  2. Study sites: 101 to 102v22
  3. Study sites: 97 to 101v21
  4. Site details revised at 4 of 97 sitesv20
  5. Study sites: 96 to 97v19
  6. Site details revised at 1 of 96 sitesv18
  7. Study sites: 95 to 96v17
  8. Study sites: 92 to 95
    • Secondary endpoints revised (20)
    v16
  9. Site details revised at 1 of 92 sitesv15
  10. Study sites: 90 to 92v14
  11. Study sites: 89 to 90v13
  12. Re-verified, no change to tracked fieldsv12
  13. Study sites: 87 to 89v11
  14. Study sites revised (87)v10
  15. Study sites: 80 to 87v9
  16. Study sites: 79 to 80v8
  17. Study sites: 74 to 79v7
  18. Trial status: Not Yet Recruiting to Recruiting
    • Study sites revised (74)
    v6
  19. Study sites: 73 to 74v5
  20. Site details revised at 2 of 73 sitesv4
  21. Study sites: 70 to 73v3
  22. Study sites: 65 to 70v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
269 trials monitored
See 14 trials at risk
Obesity
3,903 trials monitored
See 160 trials at risk
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Trial Details
NCT Number NCT06571383
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Obesity
Related terms Obesity
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov